POCML 4 Inc. Announces the Signing of Two Cannabis Concentrate Program Agreements by MediPharm Labs Inc.

POCML 4 Inc. (TSXV:POCM) (“POCML”) is pleased to announce that MediPharm Labs Inc. (“MediPharm”) has entered into Cannabis Concentrate Program Agreements with each of James E. Wagner Cultivation Corporation (TSXV:JWCA) (“JWC”) and Bonify (“Bonify”), collectively (the “Companies”). Pursuant to the agreements, the Companies have entered into commercial arrangements whereby each of JWC and Bonify will provide MediPharm with dried cannabis to use for the purposes of creating purity-assured cannabis oil (the “Program”). The Programs will be for an initial term of three years and one year respectively.

Pat McCutcheon, MediPharm’s President and Chief Executive Officer, said: “We are very excited to provide an oil extraction strategy to such innovative leaders in the cannabis space. With a robust pipeline of opportunities, we look forward to entering into additional agreements.”

MediPharm is a medicinal cannabis company specializing in the pharmaceutical production of cannabis oil products as a Licensed Producer by Health Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR), and is the first company in Canada to become a Licensed Producer for cannabis oil production without first receiving a cannabis cultivation licence. MediPharm is research-driven and focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. This expert focus on cannabis concentrates under cGMP (current Good Manufacturing Practices) utilizing ISO standard clean rooms and critical environments laboratories, allows MediPharm to work with Health Canada approved cultivation partners to produce pharmaceutical-grade cannabis oil with a competitive advantage.

Subject to the bulk transfer approval of Health Canada, each of JWC and Bonify will ship dried cannabis to MediPharm which MediPharm will use to produce cannabis oil. The Companies intend that under the Program, MediPharm may provide cannabis oil to the Companies or to other licensed producers of medical cannabis at the direction of the Companies. Alternatively, the Companies may release the cannabis extract for use by MediPharm. The Program will be established at no capital cost to the Companies; however, MediPharm will charge the Companies processing fees for the cannabis oil produced, and the revenue earned on the respective sales of cannabis oil by MediPharm will be shared between MediPharm and each of the Companies respectively.

POCML has entered into a definitive agreement with MediPharm that will govern the previously announced proposed business combination between POCML and MediPharm (the “Transaction”).  As previously announced, the Transaction will result in a reverse take-over of POCML by the shareholders of MediPharm and is intended to constitute the “Qualifying Transaction” of POCML as such term is defined in the policies of the TSX Venture Exchange.

About James E. Wagner Cultivation Corporation

JWC’s wholly-owned subsidiary is a Licensed Producer under the ACMPR. JWC is a premium cannabis brand, focusing on producing clean, consistent cannabis using an advanced and proprietary aeroponic platform named GrowthStorm™. JWC was founded as a family company and prides itself on its family values. JWC began as a collective of patients and growers under the Marijuana Medical Access Regulations (the precursor to ACMPR). Since its inception, JWC has remained focused on providing the best possible patient experience. JWC’s operations are based in Kitchener, Ontario.

For additional information about JWC, please refer to JWC’s website: www.jwcmed.com/home.html

About Bonify

Bonify is a Canadian-owned Licensed Producer under the ACMPR and leading provider of medical cannabis. By maximizing research findings and strictly adhering to best-in-class practices, quality standards and procedures, Bonify produces medical cannabis products to help individuals get the most out of life each and every day. With over 1,000,000 square feet of potential productive capacity at its present site in Winnipeg, Manitoba, Canada, when at full scale, Bonify will be capable of growing over 100,000 kg of cannabis annually.

For additional information about Bonify, please refer to Bonify’s website: www.bonify.com.

About MediPharm Labs Inc.

Founded in 2015, MediPharm is a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the Access to Cannabis for Medical Purposes Regulations (ACMPR) without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm to work with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade cannabis oil with a competitive advantage. MediPharm is research-driven and focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. MediPharm provides B2B contract processing of cannabis to Canadian authorized licensed producers and appropriate international growers, supplying integrity-assured cannabis oil to qualified companies for sale under their own brand. In addition, MediPharm will supply raw materials, formulations, processing and packaging for the creation of ready-to-sell advanced derivative products. Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.

For additional information about MediPharm, please see MediPharm’s website: www.medipharmlabs.com.

Further Information

For additional information, please contact:

David D’Onofrio, Chief Executive Officer, Chief Financial Officer, Secretary and Director, POCML 4 Inc.

Email: ddonofrio@poweronecapital.com

Patrick McCutcheon, President, Chief Executive Officer and Director, MediPharm Labs Inc.

Email: pmccutcheon@medipharmlabs.com

NEITHER THE TSXV NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to the terms and conditions of the proposed Transaction and Programs. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; and the delay or failure to receive board, shareholder or regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, POCML and MediPharm assume no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

Subsequent to this press release, MediPharm Labs Corp. went public on October 4, 2018 under the ticker symbol TSXV:LABS.

Source: www.nasdaq.com